Cronos Group Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Cronos Group stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRON, but not buy additional shares or sell existing shares.
View analyst ratings for Cronos Group or view top-rated stocks.

Wall Street analysts have given Cronos Group a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cronos Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cronos Group is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Cronos Group.

Cronos Group Inc. (NASDAQ:CRON) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.35. The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $22.19 million. Cronos Group had a negative trailing twelve-month return on equity of 11.39% and a negative net margin of 610.02%. The business's quarterly revenue was up 57.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.20 earnings per share.
View Cronos Group's earnings history.

Cronos Group's stock was trading at $5.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRON stock has increased by 64.7% and is now trading at $8.91.
View which stocks have been most impacted by COVID-19.

6 equities research analysts have issued twelve-month price objectives for Cronos Group's shares. Their forecasts range from $5.00 to $12.50. On average, they anticipate Cronos Group's stock price to reach $8.80 in the next year. This suggests that the stock has a possible downside of 1.2%.
View analysts' price targets for Cronos Group or view top-rated stocks among Wall Street analysts.

Some companies that are related to Cronos Group include Canopy Growth (CGC), Tilray (TLRY), STADA Arzneimittel Aktiengesellschaft (STDAF), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Sundial Growers (SNDL), HEXO (HEXO), ChromaDex (CDXC), Canopy Rivers (RIV), MediWound (MDWD), Natural Alternatives International (NAII), Charlie's (CHUC), Mannatech (MTEX), FitLife Brands (FTLF) and Nutra Pharma (NPHC).
View all of CRON's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include (CGC), Aurora Cannabis (ACB), Tilray (TLRY), (APHA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and OrganiGram (OGI).

Cronos Group trades on the NASDAQ under the ticker symbol "CRON."

Cronos Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Chescapmanager LLC (2.38%), Mirae Asset Global Investments Co. Ltd. (0.34%), Morgan Stanley (0.34%), TD Asset Management Inc. (0.32%), Millennium Management LLC (0.31%) and D. E. Shaw & Co. Inc. (0.31%). Company insiders that own Cronos Group stock include Jason Marc Adler, Michael Ryan Gorenstein and Todd Kevin Abraham.
View institutional ownership trends for Cronos Group.

CRON stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Asset Management Americas Inc., Goldman Sachs Group Inc., Virtu Financial LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Dynamic Technology Lab Private Ltd, Vontobel Holding Ltd., and Chescapmanager LLC. Company insiders that have sold Cronos Group company stock in the last year include Jason Marc Adler, and Michael Ryan Gorenstein.
View insider buying and selling activity for Cronos Group or view top insider-selling stocks.

CRON stock was purchased by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., Morgan Stanley, Penserra Capital Management LLC, TD Asset Management Inc., Blair William & Co. IL, Wealth Advisory Solutions LLC, AdvisorShares Investments LLC, and Credit Suisse AG.
View insider buying and selling activity for Cronos Group or or view top insider-buying stocks.

Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRON stock can currently be purchased for approximately $8.91.

Cronos Group has a market capitalization of $3.31 billion and generates $46.72 million in revenue each year. The company earns $-73,140,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

Cronos Group employs 631 workers across the globe.

The official website for Cronos Group is www.thecronosgroup.com.

Cronos Group is headquartered at 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9.

Cronos Group's mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The company can be reached via phone at 416-504-0004.